Evofem Biosciences (EVFM) Competitors $0.0094 +0.00 (+4.44%) As of 05/21/2025 01:28 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesSEC FilingsSustainabilityTrendsBuy This Stock EVFM vs. CANF, OGEN, SPRC, MBIO, GLTO, SBFM, IMCC, KZIA, SXTP, and CNSPShould you be buying Evofem Biosciences stock or one of its competitors? The main competitors of Evofem Biosciences include Can-Fite BioPharma (CANF), Oragenics (OGEN), SciSparc (SPRC), Mustang Bio (MBIO), Galecto (GLTO), Sunshine Biopharma (SBFM), IM Cannabis (IMCC), Kazia Therapeutics (KZIA), 60 Degrees Pharmaceuticals (SXTP), and CNS Pharmaceuticals (CNSP). These companies are all part of the "pharmaceutical products" industry. Evofem Biosciences vs. Can-Fite BioPharma Oragenics SciSparc Mustang Bio Galecto Sunshine Biopharma IM Cannabis Kazia Therapeutics 60 Degrees Pharmaceuticals CNS Pharmaceuticals Can-Fite BioPharma (NYSE:CANF) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment, community ranking and profitability. Which has better valuation & earnings, CANF or EVFM? Evofem Biosciences has higher revenue and earnings than Can-Fite BioPharma. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCan-Fite BioPharma$674K5.44-$7.63M-$1.79-0.58Evofem Biosciences$11.39M0.09$52.98M-$0.05-0.19 Do analysts prefer CANF or EVFM? Can-Fite BioPharma presently has a consensus target price of $14.00, suggesting a potential upside of 1,251.35%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Can-Fite BioPharma is more favorable than Evofem Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Can-Fite BioPharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Evofem Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer CANF or EVFM? In the previous week, Evofem Biosciences had 4 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 4 mentions for Evofem Biosciences and 0 mentions for Can-Fite BioPharma. Can-Fite BioPharma's average media sentiment score of 0.00 equaled Evofem Biosciences'average media sentiment score. Company Overall Sentiment Can-Fite BioPharma Neutral Evofem Biosciences Neutral Is CANF or EVFM more profitable? Can-Fite BioPharma has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Can-Fite BioPharma's return on equity of 0.00% beat Evofem Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Can-Fite BioPharmaN/A N/A N/A Evofem Biosciences -46.42%-91.97%-61.93% Do insiders & institutionals believe in CANF or EVFM? 21.0% of Can-Fite BioPharma shares are owned by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by insiders. Comparatively, 0.2% of Evofem Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more volatility and risk, CANF or EVFM? Can-Fite BioPharma has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Comparatively, Evofem Biosciences has a beta of -1, suggesting that its share price is 200% less volatile than the S&P 500. Does the MarketBeat Community believe in CANF or EVFM? Evofem Biosciences received 252 more outperform votes than Can-Fite BioPharma when rated by MarketBeat users. Likewise, 69.50% of users gave Evofem Biosciences an outperform vote while only 12.20% of users gave Can-Fite BioPharma an outperform vote. CompanyUnderperformOutperformCan-Fite BioPharmaOutperform Votes1012.20%Underperform Votes7287.80% Evofem BiosciencesOutperform Votes26269.50% Underperform Votes11530.50% SummaryCan-Fite BioPharma beats Evofem Biosciences on 11 of the 18 factors compared between the two stocks. Get Evofem Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVFM vs. The Competition Export to ExcelMetricEvofem BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.07M$6.53B$5.38B$8.39BDividend YieldN/A2.65%5.21%4.10%P/E Ratio-0.028.9226.8019.71Price / Sales0.09252.24389.55117.28Price / CashN/A65.8538.2534.62Price / Book0.006.466.804.50Net Income$52.98M$143.98M$3.23B$248.18M7 Day PerformanceN/A2.03%1.53%0.23%1 Month PerformanceN/A4.11%10.05%12.39%1 Year PerformanceN/A-2.87%16.75%7.07% Evofem Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVFMEvofem Biosciences0.1856 of 5 stars$0.01+4.4%N/A-32.4%$1.07M$11.39M-0.02120News CoverageGap UpCANFCan-Fite BioPharmaN/A$1.10-0.9%$14.00+1,172.7%-57.7%$3.89M$674,000.00-0.618OGENOragenicsN/A$0.18+6.8%N/A-93.7%$3.87M$40,000.00-0.035SPRCSciSparc0.6216 of 5 stars$0.35+2.3%N/A-75.0%$3.81M$1.31M0.004Gap DownMBIOMustang Bio0.3652 of 5 stars$1.13-3.0%$100.00+8,749.6%-92.3%$3.74MN/A-0.01100Positive NewsGap DownGLTOGalecto1.649 of 5 stars$2.78+1.3%$10.00+260.4%-80.9%$3.67MN/A-0.1440SBFMSunshine Biopharma1.8366 of 5 stars$1.35+8.0%$15.00+1,011.1%+76.3%$3.65M$34.87M-0.013Earnings ReportGap DownIMCCIM Cannabis0.6129 of 5 stars$1.61-2.4%N/A-55.1%$3.60M$54.03M-0.47340Positive NewsEarnings ReportKZIAKazia Therapeutics2.1292 of 5 stars$3.56-1.7%$57.50+1,515.2%-75.7%$3.59M$2.31M0.0012Positive NewsSXTP60 Degrees Pharmaceuticals0.6296 of 5 stars$2.42+1.3%N/A+68.4%$3.57M$607,574.00-0.243Earnings ReportGap UpCNSPCNS Pharmaceuticals1.3045 of 5 stars$1.21+6.1%$25.00+1,966.1%-99.8%$3.56MN/A-0.025Earnings Report Related Companies and Tools Related Companies Can-Fite BioPharma Alternatives Oragenics Alternatives SciSparc Alternatives Mustang Bio Alternatives Galecto Alternatives Sunshine Biopharma Alternatives IM Cannabis Alternatives Kazia Therapeutics Alternatives 60 Degrees Pharmaceuticals Alternatives CNS Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVFM) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evofem Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evofem Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EVFM Stock Free EVFM Stock Alerts